Diadema Partners LP Invests $1.22 Million in Denali Therapeutics Inc. (NASDAQ:DNLI)

Diadema Partners LP bought a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 60,000 shares of the company’s stock, valued at approximately $1,223,000.

Other hedge funds also recently added to or reduced their stakes in the company. Sterling Capital Management LLC grew its stake in shares of Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock worth $36,000 after acquiring an additional 1,516 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after purchasing an additional 885 shares during the last quarter. KBC Group NV increased its stake in Denali Therapeutics by 75.8% during the 4th quarter. KBC Group NV now owns 6,334 shares of the company’s stock valued at $129,000 after purchasing an additional 2,731 shares in the last quarter. AlphaQuest LLC lifted its stake in shares of Denali Therapeutics by 177.1% during the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company’s stock worth $142,000 after buying an additional 4,449 shares during the period. Finally, E Fund Management Co. Ltd. grew its holdings in shares of Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company’s stock valued at $204,000 after buying an additional 2,436 shares during the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Stock Up 3.2 %

DNLI opened at $13.15 on Tuesday. The company has a market cap of $1.91 billion, a price-to-earnings ratio of -4.76 and a beta of 1.58. The firm’s fifty day simple moving average is $15.47 and its two-hundred day simple moving average is $21.11. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, research analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Robert W. Baird assumed coverage on Denali Therapeutics in a research report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price target for the company. Cantor Fitzgerald raised Denali Therapeutics from a “neutral” rating to an “overweight” rating in a report on Thursday, April 10th. HC Wainwright raised their price target on shares of Denali Therapeutics from $80.00 to $87.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics in a research note on Tuesday, February 11th. They issued a “buy” rating and a $31.00 price objective on the stock. Finally, Oppenheimer reduced their target price on shares of Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. One analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $37.57.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.